Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$11.74 USD

11.74
4,304,695

+2.54 (27.61%)

Updated Nov 7, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine

by Zacks Equity Research

Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.

Sweta Jaiswal, FRM headshot

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

by Sweta Jaiswal, FRM

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Emergent (EBS) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.

Emergent Biosolutions (EBS) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 150.00% and 1.28%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.

Will Emergent Biosolutions (EBS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

by Zacks Equity Research

Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate

by Zacks Equity Research

Novovax (NVAX) announces plans to initiate clinical study to evaluate its coronavirus vaccine candidate in May, weeks ahead of schedule.

4 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Sanghamitra Saha headshot

Top Sectors of Q1 & Their Winning Stocks

by Sanghamitra Saha

Inside the top-performing sectors of Q1 and their winning stocks.

Why Is Emergent Biosolutions (EBS) Down 23.6% Since Last Earnings Report?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMV to Develop Vaccine Candidate Against COVID-19, Shares Up

by Zacks Equity Research

IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

Emergent (EBS) Begins Development of Treatments for COVID-19

by Zacks Equity Research

Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.

Emergent BioSolutions Collaborates for Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View

by Zacks Equity Research

Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

by Zacks Equity Research

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

by Zacks Equity Research

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

by Zacks Equity Research

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

by Zacks Equity Research

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals